Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Are atypical antipsychotics associated with a reduced risk of developing parkinsonism?

Nature Clinical Practice Neurology volume 2, pages 132–133 (2006)Cite this article

boxed-textRochon PA et al. (2005) Atypical antipsychotics and parkinsonism. Arch Intern Med 165: 1882–1888

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Schneider LS et al. (2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294: 1934–1943

    Article  CAS  Google Scholar 

  2. Deberdt WG et al. (2005) Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry 13: 722–730

    Article  Google Scholar 

  3. Lieberman JA et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209–1223

    Article  CAS  Google Scholar 

  4. Katz IR et al. (1999) Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 60: 107–115

    Article  CAS  Google Scholar 

  5. Fernandez HH et al. (2003) Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 26: 643–659

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Christine Kyme, Assistant Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Department of Clinical Neurosciences at Brown University, Providence, RI, USA

    Kelvin L Chou & Joseph H Friedman

  2. NeuroHealth Parkinson's Disease and Movement Disorders Center, Warwick, RI, USA

    Kelvin L Chou & Joseph H Friedman

Authors
  1. Kelvin L Chou
    View author publications

    Search author on:PubMed Google Scholar

  2. Joseph H Friedman
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Kelvin L Chou.

Ethics declarations

Competing interests

J Friedman has received funds within the last 12 months for consulting, lecturing or research from the following involved companies: Astra Zeneca, Janssen, Novartis, Ovation and Acadia Pharmaceutical companies. K Chou has received funds from the following companies for lecturing or research: GlaxoSmithKline, Novartis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chou, K., Friedman, J. Are atypical antipsychotics associated with a reduced risk of developing parkinsonism?. Nat Rev Neurol 2, 132–133 (2006). https://doi.org/10.1038/ncpneuro0129

Download citation

  • Received:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncpneuro0129

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing